Yee Ju Visit 1: A 62-year-old woman presenting with dyspnea and cough

Title:

Yee Ju Visit 1: A 62-year-old woman presenting with dyspnea and cough

Topic: Hematology-Oncology
Relevant Terms: Advanced Non-small Cell Lung Cancer, Cancer, Non-Small-Cell Lung Cancer
Primary Audience: Oncologists and other healthcare providers that treat and care for elderly cancer patients.
Launch Date: 07-May-13
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Managing NSCLC in elderly patients

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Identify potential surrogate endpoints in order to improve evaluation of patients with NSCLC
  2. Incorporate patients' questions and concerns regarding maintenance therapy when developing treatment plans in order to better address their individual needs
  3. Identify elderly patients with NSCLC who would benefit from maintenance therapy in order to improve progression-free survival

    Faculty

    Paul A. Bunn, Jr., MD
    Professor, Medicine and Cancer Center
    University of Colorado School of Medicine;
    Professor, Cancer Center
    University of Colorado Hospital
    Executive Director, International Association for the Study of Lung Cancer
    Aurora, CO
    David S. Ettinger, MD, FACP, FCCP
    Alex Grass Professor of Oncology
    The John Hopkins University School of Medicine
    Active Staff, Department of Oncology
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, MD
    Mark A. Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section, Division of Hematology Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh, UPMC Cancer Pavilion
    Pittsburgh, PA
    PROGRAM OVERVIEW:
    Lung cancer is the leading cause of mortality in men and women, and non-small-cell lung cancer (NSCLC) in particular, continues to pose a significant public health problem, as it is the leading cause of cancer-related deaths in both men and women in the US. The majority of patients with NSCLC are in the later years of their lives; in a recent Surveillance, Epidemiology and End Results database analysis, 47% of the patients diagnosed with NSCLC were at least 70 years old and 14% were at least 80 years old. Overall survival (OS) is significantly inferior in the elderly, usually as a result of underlying comorbidities, poor performance status and concomitant illnesses.
     
    NSCLC, including squamous carcinoma, adenocarcinoma and large cell carcinoma, accounts for more than 80% of all lung cancers, but in recent decades, major improvements have been achieved in the treatment of advanced NSCLC. The current standard of first-line therapy for NSCLC consists of platinum-based doublet progressive disease. However, this practice is evolving with the promising rise of targeted therapies in the treatment of NSCLC. 
     
    Maintenance Therapy (MT) is one strategy that has gained attention recently as a way of improving outcomes of patients with NSCLC. For example, a recent metaanalysis identified eight randomized clinical trials which showed that MT with either a continuous or a switch strategy significantly increased OS and progression-free survival (PFS) compared with placebo. Since most patients who obtain disease control experience disease progression only 2-3 months after the end of first-line chemotherapy, MT is a strategy that has gained much interest. The principle of MT is to prolong disease control obtained with first-line chemotherapy by additional therapy, in an attempt to improve overall survival (OS), with preserved Quality of Life (QoL).
     
    This program will focus on MT and the therapeutic options available for NSCLC. We aim to provide clinicians with a firm base of knowledge that they can apply to their clinical practice in order to make more sound treatment decisions, and eventually enhance patient outcomes.

    Course Topic
    :  NSCLC
     
    Target Audience:
    This activity has been designed to meet the educational needs of oncologists and other healthcare providers involved in treating cancer patients and the elderly.
     
    Faculty
    Activity Leader:
     
    Paul A. Bunn, Jr., MD
    Professor, Medicine and Cancer Center
    University of Colorado School of Medicine;
    Professor, Cancer Center
    University of Colorado Hospital
    Executive Director, International Association for the Study of Lung Cancer
    Aurora, CO
     
    Consulting Faculty:
     
    David S. Ettinger, MD, FACP, FCCP
    Alex Grass Professor of Oncology
    The John Hopkins University School of Medicine
    Active Staff, Department of Oncology
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, MD
     
    Mark A. Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section, Division of Hematology Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh, UPMC Cancer Pavilion
    Pittsburgh, PA
     
    CME Advisory Committee
     
    Course Director/Course Reviewer
     
    M. Susan Burke, MD, FACP
    Clinical Assistant Professor, Internal Medicine
    Thomas Jefferson University Medical School
    Senior Advisor, Internal Medicine Clinical Care Center
    Lankenau Hospital
    Wynnewood, PA
     
    Planning Committee
     
    Joshua Kilbridge
    President
    Kilbridge Associates
    Healthcare Communications
     
    Kelly Kraines
    General Manager
    Med Learning Group
     
    Christopher Cahill
    Associate Director, Planning and Projects
    Med Learning Group
     
     
    DISCLOSURE POLICY STATEMENT:
    In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
     
    DISCLOSURE OF CONFLICTS OF INTEREST:
     
    Faculty
     
    Paul A. Bunn, Jr., MD
    Disclosure: Dr. Bunn receives consulting fees from Amgen, Astellas Pharma US, Inc., AstraZeneca, Bayer, Biodesix, Boehringher Ingelheim, Bristol-Myers Squibb, Celgene, EMD Serono, Inc., Daiichi Sankyo, Genentech/Roche, Gilead Science, Inc., GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Inc., Myriad, Novarits, Pfizer, sanofi-aventis, and Synta Pharmaceuticals, Corp.
     
    David S. Ettinger, MD
    Disclosure: Dr. Ettinger receives consulting fees from Biodesix. Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Science, Inc., and Genentech/Roche.
     
    Mark A. Socinski, MD
    Disclosure: Dr. Socinski is on the Speakers' Bureau for Celgene, Eli Lilly and Company, and Genentech/Roche.  Dr. Socinski receives contracted research fees from Celgene, Eli Lilly and Company, Genentech/Roche, Merrimack Pharmaceuticals, Inc., Pfizer and Synta Pharmaceuticals Corp.  
     
    M. Susan Burke, MD, FACP
    Disclosure: Dr. Burke is on the Speakers' Bureaus for Merck & Co., Inc. Dr. Burke also receives consulting fees from Iroko Pharmaceuticals.
     
    Planning Committee
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Joshua Kilbridge of Kilbridge Associates has no relevant financial relationships to disclose.
     
    Kelly Kraines of Med Learning Group has no relevant financial relationships to disclose.
     
    Christopher Cahill, of Med Learning Group has no relevant financial relationships to disclose.
     
     
    ACCREDITATION STATEMENT:
    Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    This CME activity was planned and produced in accordance with the ACCME Essentials.
    For CME questions, please contact: Med Learning Group at info@medlearninggroup.com
    Contact this CME provider for privacy and confidentiality policy statement information at:
    http://www.medlearninggroup.com/?page_id=865
     
    CREDIT DESIGNATION STATEMENT:
    Med Learning Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    TO OBTAIN CME CREDITS:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit.
    • You must score 60% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Disclaimer
    Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    DISCLOSURE OF UNLABLED USE:
    Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
     
    COURSE VIEWING REQUIREMENTS:
    Google Chrome for Windows, Mac, or Linux
    Internet Explorer 7.0+ for Windows
    Mozilla 1.4+ for Windows, Mac, or Linux
    Firefox 3.5+ for Windows, Mac, or Linux
    Safari 4.0+ for Mac
     
    Release Date: May 7, 2013
    Expiration Date: May 7, 2014
     
    MEDIUM: Internet
     
    ACKNOWLEDGEMENT:
    This activity is sponsored by Med Learning Group.



    This activity is supported by an educational grant from Lilly USA, LLC.


    If you have any questions regarding this activity, send an email to info@medlearninggroup.com.
     
    This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields.  
     
    Copyright © 2013 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.